Axon Enterprise Inc vs Tilray Brands Inc — how do they compare? Axon Enterprise Inc trades at $597.69 (market cap $51.69B), while Tilray Brands Inc trades at $4.74 (market cap $649.42M). The key difference: Axon Enterprise Inc is far larger — about 79.6× Tilray Brands Inc's market cap, and Axon Enterprise Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| AXON | TLRY | |
|---|---|---|
Market Cap | $51.69B | $649.42M |
Sector | Technology | Health |
52-Week High | $791.62 | $21.00 |
52-Week Low | $345.94 | $3.88 |
Enterprise Value | $52.83B | $816.55M |
Signals from Pluang's Aura AI — not financial advice
Axon Enterprise trades at $595.63, showing slight consolidation after recent strength with a bullish technical outlook. The company delivered strong Q2 2026 results with 35% revenue growth and raised full-year guidance, though valuation metrics remain elevated with a P/E of 265. Analyst sentiment is overwhelmingly positive with 81% buy ratings and a $685 consensus target.
Axon's razor-and-blade model drives hardware adoption and high-margin software growth, supported by AI capabilities and $15.1B in future contracted bookings. Key risks include valuation concerns, gross margin pressure from service mix, and execution challenges in scaling new products. The stock offers growth exposure but requires monitoring of margin trends.
TLRY trades at $4.77, up 7.92% in the last session, with a bullish technical signal from moving averages but mixed oscillators. The company reported record fiscal 2026 revenue of $915 million (GlobeNewsWire, July 28, 2026) but posted a net loss. Key financials show a low P/S of 0.58 and P/B of 0.4, yet profitability remains challenged with negative net income margins and ROE.
Outlook is cautiously optimistic due to revenue growth and diversification into beverages and wellness, but high execution risk persists from consistent losses and competitive pressures. Analyst sentiment is mixed with 25% buy ratings, suggesting potential upside if profitability improves, though near-term volatility is likely.
Trailing returns across standard periods
Latest headlines on both assets
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →